Current State of Combination of Locoregional Therapies with Immune Checkpoint Inhibition.

Advances in immunotherapy have changed the landscape of oncology over the past decade. Still, most patients with solid organ tumors do not derive a durable benefit from immunotherapies. How these tumors evade treatment has not been fully elucidated, but several studies are seeking ways to stimulate treatment response in these immunologically quiescent tumors. Of these, the combination of locoregional therapy with immune checkpoint inhibition is of interest to the interventional radiologist. This brief report provides an overview of current trials testing the effectiveness of locoregional therapy in combination with immune checkpoint inhibitors and identifies future research goals.